Navigation Links
PDL BioPharma Announces European Patent Office Determination of Validity of PDL's European Patent is Final
Date:2/28/2011

INCLINE VILLAGE, Nev., Feb. 28, 2011 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) announced today that the Technical Board of Appeal of the European Patent Office (EPO) has cancelled its hearing in which three appellants sought to have a 2007 decision upholding PDL's  European Patent No. 0 451 216B (the '216B Patent) overturned and the patent revoked. The effect of the termination of the opposition appeal proceeding is that the 2007 EPO decision upholding the claims of PDL's '216B Patent as valid will become the final decision of the EPO. The hearing was scheduled for February 28 and March 1, 2011.  In the year ended December 31, 2010, approximately 35 percent of PDL's revenues were derived from sales of products that were made in Europe and sold outside of the United States. These revenues could have been negatively impacted or eliminated entirely by an adverse ruling at the hearing.  

In an opposition proceeding brought by multiple parties, the Opposition Division of the EPO found in 2007 the claims of the '216B Patent to be valid. Five of the opposing parties filed notices of appeal to the Technical Board of Appeal of the EPO seeking to have the decision of the Opposition Division upholding the '216B Patent overturned and the patent revoked. Three of those parties filed detailed grounds of appeal:  UCB Pharma S.A., BioTransplant Incorporated whose counsel PDL believes has been financially supported by MedImmune LLC, and Novartis AG. Pursuant to PDL's recent settlements with UCB, MedImmune and Novartis, which were previously announced, and as a result of PDL's recent acquisition of BioTransplant out of bankruptcy and subsequent withdrawal of their appeal, all of the active appellants have formally withdrawn their participation in the appeal proceeding. Accordingly, the EPO cancelled the appeal hearing, terminated the opposition proceeding and
'/>"/>

SOURCE PDL BioPharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. PDL BioPharma Announces Regular Quarterly Dividend Policy
2. PDL BioPharma to Present at Upcoming Conferences
3. Enox Biopharma, Inc. to Present at IN3 West Investment in Innovation Conference.
4. Success Factors and Failure Points in Biopharmaceutical Product Launches
5. Plato BioPharma, Inc Appoints New Board Member
6. UCB and PDL BioPharma Resolve Patent Disputes
7. Inspiration Biopharmaceuticals Demonstrates Non-Inferiority of IB1001, Its Recombinant Factor IX for Hemophilia B
8. Laureate Pharma Changes Name to Laureate Biopharmaceutical Services, Inc.
9. PDL BioPharma Appoints Caroline Krumel as Vice President of Finance and Thanks Karen Wilson for her Contributions
10. Enox Biopharma, Inc. to Present at OneMedForum Emerging Company Finance Conference.
11. Genesis Biopharma to Present at 2011 Biotech Showcase Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... MARSEILLE , Frankreich, July ... , Weltweite Exklusivlizenz der Universität ... Entwicklung von Tests auf SF3B1-Mutationen, einschließlich von ... Neuer Test weist Mutationen des SF3B1-Gens nach, ... einen günstigen Krankheitsverlauf vermuten lassen  ...
(Date:7/24/2014)... Inc. (NasdaqGS: ABAX ), a medical products ... results for the first fiscal quarter ended June 30, ... of $47.5 million, up 10% over last year,s comparable ... over last year,s comparable quarter. Revenues highlights: ... 20% over last year,s comparable quarter. , Veterinary ...
(Date:7/24/2014)... THOUSAND OAKS, Calif. , July 24, 2014 ... will report its second quarter financial results on Tuesday, July ... The announcement will be followed by a conference call with ... call from Amgen will be Robert A. Bradway , ... senior management team. Live audio of the conference ...
Breaking Medicine Technology:QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 2QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 3QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 4QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 5Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 2Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 3Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 4Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 5Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 6Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 7Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 8Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 9Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 10Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 11Amgen Announces Webcast of 2014 Second Quarter Financial Results 2
... Calif., March 19, 2012 diaDexus, Inc. (OTC Bulletin ... proprietary cardiovascular diagnostic products, today highlighted data from two ... Test for Lp-PLA(2)  Activity.  The PLAC® Test for Lp-PLA(2) ... States and is an investigational assay in the United ...
... 2012  Nouveau Life Pharmaceuticals, soon to be changed from ... announced today that Advent Financial, a leading financial analyst ... 5-year revenue for the Company at $42MM.  Advent has ... experience at large investment banks including Bank of America, ...
Cached Medicine Technology:diaDexus, Inc. Highlights Findings from Two Outcomes Studies for its PLAC Lp-PLA(2) Activity Assay 2diaDexus, Inc. Highlights Findings from Two Outcomes Studies for its PLAC Lp-PLA(2) Activity Assay 3diaDexus, Inc. Highlights Findings from Two Outcomes Studies for its PLAC Lp-PLA(2) Activity Assay 4diaDexus, Inc. Highlights Findings from Two Outcomes Studies for its PLAC Lp-PLA(2) Activity Assay 5diaDexus, Inc. Highlights Findings from Two Outcomes Studies for its PLAC Lp-PLA(2) Activity Assay 6Leading Financial Analyst Group Estimates 5-Year Revenue for HRID at $42MM 2
(Date:7/25/2014)... (PRWEB) July 26, 2014 According ... Monitoring Market by Product (vibration monitoring, thermography, ultrasound ... signature analysis), Component, Application and Geography - Global ... the machine health monitoring market is expected to ... 2014 to 2020. , Browse 117 market data ...
(Date:7/25/2014)... New York, NY (PRWEB) July 25, 2014 ... cut ticket prices across the board for the Guinness ... Liverpool FC and Olympiacos FC at Soldier Field ... is also offering their customer appreciation promo/coupon/offer code SOCCER-2014 ... be an amazing year for diehard soccer fans in ...
(Date:7/25/2014)... As reported by Wood TV 8 in the ... has seen a nearly 500-person increase in heroin related overdose ... 271 between 1999 and 2002, the toll increased to 728 ... other states, drug users in Michigan have turned to heroin ... compared the price of both substances, noting that an 80-milligram ...
(Date:7/25/2014)... -- The human brain can preserve oxygen to protect ... finds. Although dehydration significantly reduces blood flow ... the brain compensates by increasing the amount of oxygen ... helped us understand a lot more about how the ... study first author Steven Trangmar, a researcher at Brunel ...
(Date:7/25/2014)... Ticket Down is a reliable source for cheap ... California Memorial Stadium. With the post-World Cup emotions still rolling ... the 2014 Guinness International Champions Cup have brought eight of ... representing La Liga, English Premier League, Serie A, and Superleague ... players from around the world to 12 American cities and ...
Breaking Medicine News(10 mins):Health News:Machine Health Monitoring Market by Product, Component & Application Worth $2.50 Billion by 2020 - New Report by MarketsandMarkets 2Health News:Machine Health Monitoring Market by Product, Component & Application Worth $2.50 Billion by 2020 - New Report by MarketsandMarkets 3Health News:Machine Health Monitoring Market by Product, Component & Application Worth $2.50 Billion by 2020 - New Report by MarketsandMarkets 4Health News:Liverpool FC vs. Olympiacos FC Tickets Soldier Field: Ticket Down Slashes Ticket Prices for Guinness International Champions Cup in Chicago on Sunday, July 27th 2Health News:Rise in Heroin Use, Overdose Deaths in Michigan 2Health News:Human Brain Has Coping Mechanism for Dehydration 2Health News:Real Madrid vs. Inter Milan Tickets Berkeley: Ticket Down Slashes Ticket Prices on Guinness International Champions Cup Tickets at California Memorial Stadium 2Health News:Real Madrid vs. Inter Milan Tickets Berkeley: Ticket Down Slashes Ticket Prices on Guinness International Champions Cup Tickets at California Memorial Stadium 3
... WuXi PharmaTech (Cayman) Inc.,(NYSE: WX ), a ... and medical device industries, with operations,in China and the ... , , (Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO ), ... 2009 Net Revenues Increase 5% Year Over Year to, ...
... Hundreds of Grass-Roots Activists and Scientific Leaders Meet in Nashville for Al ... ... -- The Climate Project (TCP), an international non-profit founded by former Vice ... climate crisis at a grassroots level worldwide, is opening its North American ...
... Quest Diagnostics Incorporated (NYSE: DGX ), the ... today announced that its Board of Directors declared a ... $0.10 per share, payable on July 20, 2009, to ... Diagnostics , Quest Diagnostics is the world,s leading ...
... MDAs policymakers consider ways to cut health costs as ... of physician practices finds that physicians on average are ... administrative tasks required by health plans. According to ... Weill Cornell Medical College and colleagues, physician practices report ...
... Health Systems, ,party philanthropy, and a caring young girl ... King Cardiac Foundation (LKCF), founded by internationally acclaimed ... its goal to Save a Heart a Day ... have received life saving cardiac treatment from the Foundation ...
... Corporation announced today that it has entered into a multi-year, sole-source ... in infant formulas and growing-up milks produced by Lactalis and sold ... ... May 14, 2009 - Martek Biosciences Corporation (NASDAQ: MATK) ...
Cached Medicine News:Health News:WuXi PharmaTech Announces First-Quarter 2009 Results 2Health News:WuXi PharmaTech Announces First-Quarter 2009 Results 3Health News:WuXi PharmaTech Announces First-Quarter 2009 Results 4Health News:WuXi PharmaTech Announces First-Quarter 2009 Results 5Health News:WuXi PharmaTech Announces First-Quarter 2009 Results 6Health News:WuXi PharmaTech Announces First-Quarter 2009 Results 7Health News:WuXi PharmaTech Announces First-Quarter 2009 Results 8Health News:WuXi PharmaTech Announces First-Quarter 2009 Results 9Health News:WuXi PharmaTech Announces First-Quarter 2009 Results 10Health News:WuXi PharmaTech Announces First-Quarter 2009 Results 11Health News:WuXi PharmaTech Announces First-Quarter 2009 Results 12Health News:WuXi PharmaTech Announces First-Quarter 2009 Results 13Health News:WuXi PharmaTech Announces First-Quarter 2009 Results 14Health News:WuXi PharmaTech Announces First-Quarter 2009 Results 15Health News:The Climate Project Brings Together Historic Gathering of World's Experts on Climate Change 2Health News:The Climate Project Brings Together Historic Gathering of World's Experts on Climate Change 3Health News:The Climate Project Brings Together Historic Gathering of World's Experts on Climate Change 4Health News:Physician practice interactions with health plans cost $31 billion a year 2Health News:Physician practice interactions with health plans cost $31 billion a year 3Health News:The Larry King Cardiac Foundation Achieves Record Life-Saving Pace With Help From New Friends and Partners 2Health News:Martek Signs Sole-Source ARA Supply Agreement with Lactalis Nutrition Sante 2Health News:Martek Signs Sole-Source ARA Supply Agreement with Lactalis Nutrition Sante 3
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Standard type 1/1 (mm), opening width 9.0 mm and length 8 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 19.0 mm and length 21 mm....
The Vitek 2 is a fully automated bacteriology system that performs bacterial identification and susceptibility testing analysis using a standard inoculum. It detects resistance and helps combat bacte...
IDS Rapid STR, a microbial identification system....
Medicine Products: